Topical Calcineurin Inhibitors and Malignancy Risk.
Context: The approval of topical calcineurin inhibitors (TCIs) has been a significant breakthrough for the treatment of atopic dermatitis due tomuchlower systemic absorption and not causing skin atrophy even after long-term use that have made them become popular replacements for topical corticostero...
| Published in: | International Journal of Cancer Management Vol. 10; no. 4; pp. 1 - 7 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Published: |
Medical Journals Commission of the Ministry of Health & Medical Education
Apr2017
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=124784372&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 124784372 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 25384422 L6AI jtl: International Journal of Cancer Management issn: 25384422 maglogo: N pubinfo: dt: Apr2017 vid: 10 iid: 4 pid: 66482 pub: Medical Journals Commission of the Ministry of Health & Medical Education artinfo: ui: 124784372 10.5812/ijcm.6173 124784372 ppf: 1 ppct: 6 formats: fmt: @attributes: type: P tig: atl: Topical Calcineurin Inhibitors and Malignancy Risk. aug: au: Radovic, Tamara Cuk Kostovic, Kresimir Ceovic, Romana Mokos, Zrinka Bukvic affil: Poliklinika Nola, Zagreb, Croatia sug: ab: Context: The approval of topical calcineurin inhibitors (TCIs) has been a significant breakthrough for the treatment of atopic dermatitis due tomuchlower systemic absorption and not causing skin atrophy even after long-term use that have made them become popular replacements for topical corticosteroids being almost equally effective. In January 2006, the US food and drug administration (FDA), followed later also by the European medicine agency (EMEA), issued the "black box" warning causing controversy regarding a potential increased risk of lymphoma in patients with atopic dermatitis and treated with TCIs. Evidence Acquisition: PubMed and MEDLINE® databases were systematically searched utilizing a variety of terms relating to the subject matter. Articles written only in English over the past 15 years were analyzed and selected for review. Results: So far, no scientific evidence of the association has been found between use of TCIs, and increased incidence of skin cancers and lymphomas in patients with AD. The systematic review and meta-analysis by Legendre et al. found the role of TCIs unlikely to be a significant risk factor of lymphoma in those patients. Conclusions: Despite an extensive body of evidence regarding the TCIs safety, the box warning still remains leaving the physicians and patients unduly uncertain and confused about the safety of TCI use. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|